French drug delivery solutions provider Aptar Pharma announced an exclusive deal with Becton, Dickinson and Company (BD) to develop and commercialize a novel auto-injector based on Aptar’s two-step device and BD’s prefillable syringes.
BD is a leading manufacturer of syringes including the BD Hypak prefillable syringe. Aptar currently markets Pro-Ject™, a relatively small, lightweight disposable auto-injector used for delivery of biologics and other drugs.
Aptar’s auto-injector was specifically designed around BD’s stable of prefilled syringes and the company claims to hold a number of patents on the design. Under the agreement, BD – a global medical technology firm – will commercialize the product.
Here is Aptar’s video showing the design features and administration of Pro-Ject:
As the device is being developed to deliver a variety of drugs across a range of applications, the economies of scale could potentially result in a lower cost alternative for epinephrine delivery.
